SPECT imaging of mice with Tc-radiopharmaceuticals obtained from Mo produced by Mo(n,2n)Mo and fission of U

Mo(n,2n)Mo反応で製造したMoとUの核分裂で製造したMoから調製したTc放射性薬剤のマウスSPECT画像

橋本 和幸; 永井 泰樹; 川端 方子; 佐藤 望*; 初川 雄一; 佐伯 秀也; 本石 章司*; 太田 雅之; 今野 力  ; 落合 謙太郎; 河内 幸正; 太田 朗生; 椎名 孝行; 竹内 宣博; 芦野 広樹; 中原 勇人*

Hashimoto, Kazuyuki; Nagai, Yasuki; Kawabata, Masako; Sato, Nozomi*; Hatsukawa, Yuichi; Saeki, Hideya; Motoishi, Shoji*; Ota, Masayuki; Konno, Chikara; Ochiai, Kentaro; Kawauchi, Yukimasa; Ota, Akio; Shiina, Takayuki; Takeuchi, Nobuhiro; Ashino, Hiroki; Nakahara, Yuto*

The distribution of Tc-radiopharmaceutical in mouse was obtained with SPECT for the first time using Tc, which was separated by thermochromatography from Mo produced via the Mo(n,2n)Mo reaction with accelerator neutrons. The SPECT image was comparable with that obtained from a fission product Mo. Radionuclidic purity and radiochemical purity of the separated Tc and its aluminum concentration met the United States Pharmacopeia regulatory requirements for Tc from the fission product Mo. These results provide important evidence that Tc radiopharmaceutical formulated using the Mo can be a promising substitute for the fission product Mo. A current and forthcoming problem to ensure a reliable and constant supply of Mo in Japan can be partially mitigated.